Changes in Hong Kong stocks | Shenwei Pharmaceutical (02877) rose more than 3%. Seluotong capsules have completed phase III clinical trials and are expected to obtain production approval next year

The Zhitong Finance App learned that Shenwei Pharmaceutical (02877) rose more than 3%. As of press release, it had risen 3.15% to HK$8.51, with a turnover of HK$10.884 million.

Guoyuan International released a research report saying that Shenwei Pharmaceutical has achieved remarkable results in innovative research in traditional Chinese medicine, and many research and clinical projects are progressing smoothly. In the first half of 2025, the company's R&D expenses were RMB 50.37 million, accounting for 3.0% of revenue. Products under development, such as Q-B-Q-F concentrate pills and seluotong capsules, are progressing steadily. The innovative drug Seluotong capsules have completed phase III clinical trials, and the data and reports required by regulations are currently being compiled. It is expected that production approval will be obtained in 2026 and marketed in 2027.

Guoyuan International pointed out that Seluotong capsules are component traditional Chinese medicine developed with modern innovative technology. It is an innovative traditional Chinese medicine for vascular dementia. Vascular dementia is the second most common cause of dementia after Alzheimer's disease. It is estimated that the number of patients with Alzheimer's disease in China will exceed 10 million in 2025. Currently, there is no effective treatment. The market space for Seluotong capsules is vast, and it will be a major variety in the future.